Immatics Announces Collaboration With Moderna
Reston – September 11, 2023 – Cooley advised Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, on its strategic collaboration with Moderna. Lawyers Kenneth Krisko and Stephanie Palmer led the Cooley team advising Immatics.
The collaboration combines Immatics’ T cell receptor (TCR) platform with Moderna’s cutting-edge mRNA technology. Immatics will receive an upfront payment of $120 million, and the company is eligible to receive development, regulatory and commercial milestone payments that could exceed $1.7 billion.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.